| scholarly article | Q13442814 |
| P356 | DOI | 10.2215/CJN.00840207 |
| P698 | PubMed publication ID | 17699475 |
| P50 | author | Katherine R Tuttle | Q89490767 |
| P2093 | author name string | Janet B McGill | |
| Douglas J Haney | |||
| Pamela W Anderson | |||
| Toni E Lin | |||
| PKC-DRS, PKC-DMES, and PKC-DRS 2 Study Groups | |||
| P433 | issue | 4 | |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 631-636 | |
| P577 | publication date | 2007-05-30 | |
| P1433 | published in | Clinical Journal of the American Society of Nephrology | Q15757929 |
| P1476 | title | Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease | |
| P478 | volume | 2 |
| Q45093431 | Association of 276G>T adiponectin gene polymorphism to plasma adiponectin and albuminuria in type 2 diabetic patients |
| Q48352610 | Chikusetsu Saponin IVa Ameliorates Cerebral Ischemia Reperfusion Injury in Diabetic Mice via Adiponectin-Mediated AMPK/GSK-3β Pathway In Vivo and In Vitro |
| Q34387952 | Diabetic nephropathy - complications and treatment |
| Q39349244 | Dual inhibition of classical protein kinase C-α and protein kinase C-β isoforms protects against experimental murine diabetic nephropathy. |
| Q39189471 | Dual protein kinase C alpha and beta inhibitors and diabetic kidney disease: a revisited therapeutic target for future clinical trials |
| Q27021632 | Early diabetic nephropathy in type 1 diabetes: new insights |
| Q37418807 | Early nephropathy in type 1 diabetes: the importance of early renal function decline |
| Q37489497 | Emerging therapies for chronic kidney disease: what is their role? |
| Q28080717 | Improvements in the Management of Diabetic Nephropathy |
| Q35125585 | New insight into the molecular drug target of diabetic nephropathy |
| Q35953867 | Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths |
| Q37904098 | Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy |
| Q34412593 | PKCδ promotes high glucose induced renal tubular oxidative damage via regulating activation and translocation of p66Shc. |
| Q38111707 | Pathophysiology of the diabetic kidney. |
| Q42040754 | Pectinase-Processed Ginseng Radix (GINST) Ameliorates Hyperglycemia and Hyperlipidemia in High Fat Diet-Fed ICR Mice |
| Q26864133 | Present and future in the treatment of diabetic kidney disease |
| Q37783417 | Progress Toward Novel Treatments for Chronic Kidney Disease |
| Q37141320 | Protein kinase C, an elusive therapeutic target? |
| Q89465079 | Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes |
| Q33654195 | Selective inhibition of protein kinase C β2 attenuates the adaptor P66 Shc-mediated intestinal ischemia-reperfusion injury |
| Q36720570 | Tandem inhibition of PKC in Diαβetic nephropathy: it takes two to tango? |
| Q37399929 | Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice |
| Q38949048 | The Gomez' equations and renal hemodynamic function in kidney disease research |
| Q30423005 | Therapeutic Modalities in Diabetic Nephropathy: Future Approaches |
| Q38209811 | Therapeutic approaches to diabetic nephropathy--beyond the RAS. |
| Q38605099 | Therapies on the Horizon for Diabetic Kidney Disease. |
| Q37980677 | What are new avenues for renal protection, in addition to RAAS inhibition? |
Search more.